4th Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$880,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain. H.R.2870: Essential Medicines Strategic Stockpile Act of 2021. AAM Blueprint to Enhance the Security of the U.S. Supply Chain. US-India Trade Discussions. TRIPS Waivers. Enhanced Access to Affordable Medicines Act. Shipping Delays.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
JONATHAN KIMBALL —
ERIK C KOMENDANT —
KATHERINE RAAB —
JOSEPH RUSSO —
CHRISTINE SIMMON —
POLLY WEBSTER —

Contacted: SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC)

Bills named: H.R. 2870 (117th)

Budget/Appropriations BUD

FDA Funding. E-Labeling Prohibition in FY22 Ag-FDA Appropriations.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ERIK C KOMENDANT —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Natl Economic Council (NEC); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); White House Office; HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Patent Settlements. H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act. H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021. Patent Abuse. H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act. Skinny Labeling. REMEDY Act. BPCIA Patent Dance. Inter Partes Review. Section 101 of the Patent Act. Product Hopping. H.R.2873/S.1435: Affordable Prescriptions for Patients Act of 2021. TAB Appointments Clause (Arthrex Case). Enhancing Quality of Patents through the PTAB. S.2891: Restoring the America Invents Act.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ERIK C KOMENDANT —
DANIEL LEONARD —
KATHERINE RAAB —
JOSEPH RUSSO —
POLLY WEBSTER —

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); White House Office; Natl Economic Council (NEC); Commerce, Dept of (DOC); U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2891 (117th), S. 1435 (117th), S. 2891 (117th), H.R. 153 (117th), H.R. 2873 (117th), S. 1428 (117th), H.R. 2884 (117th)

Medicare/Medicaid MMM

Medicare Part D Reform. Medicare Part D Program and Generic Drugs. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program. Medicare Part D Tiering. H.R.2846: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. H.R.2868: Protecting Access to Affordable Medicines Act of 2021. Medicare Price Negotiation. H.R.5260: Reduced Costs and Continued Cures Act. Medicare Shared Savings Program. H.R.2869/S.1427: Increasing Access to Biosimilars Act of 2021. ASP+8%. H.R.2815:BIOSIM Act.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ERIK C KOMENDANT —
DANIEL LEONARD —
KATHERINE RAAB —
JOSEPH RUSSO —
STEVEN SELDE —
CHRISTINE SIMMON —
POLLY WEBSTER —

Contacted: White House Office; Natl Economic Council (NEC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); Food & Drug Administration (FDA)

Bills named: S. 1427 (117th), H.R. 2868 (117th), H.R. 2815 (117th), H.R. 5260 (117th), H.R. 2846 (117th), H.R. 2869 (117th)

Pharmacy PHA

Prescription Drug Costs. Drug Pricing. Biden Executive Order on Drug Pricing. Pre-Hatch-Waxman ANDAs (PANDAs). H.R.2831: The Prompt Approval of Safe Generic Drugs Act. 180-Day Exclusivity. Forfeiture of 180-Day Exclusivity. H.R.2853: BLOCKING Act of 2021. Labeling of Generic Drugs and Biosimilars. Carter Bill on Section 505(j)(10) Labeling. Generic carveouts patent protected information in drug labels, including issues related to GSK v. Teva. Legislation to incentivize domestic manufacturing. Drug Shortages. H.R.2870: Essential Medicines Strategic Stockpile Act of 2021. Stockpile of Generic Drugs. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. Biosimilar User Fee Act (BsUFA). BsUFA III Negotiations. Biosimilars Insulin. Pass-through Payments for Biosimilars. Cost Sharing for Biosimilars. Hybrid Biosimilar Applications [Legislation not yet introduced]. Biosims Testing [Legislation not yet introduced]. H.R.2565: FDA Modernization Act of 2021 as it relates to alternative testing methods to animal testing to investigate the safety and effectiveness of a drug, and for other purposes. FDA Inspections. FDA-PTO Collaboration. Buy American Proposals. Issues Related to COVID-19. H.R.2910: Veterans Health Care Freedom Act. H.R.5376: Build Back Better Act.

Contacted: Natl Economic Council (NEC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); SENATE; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); White House Office

Bills named: H.R. 2565 (117th), H.R. 5376 (117th), H.R. 2910 (117th), H.R. 2870 (117th), H.R. 2853 (117th), H.R. 2831 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.